CLIMB BIO, INC. Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest
CLIMB BIO, INC. (CLYM) reported Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest of -$13.60 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Income Statement
us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest · last filed 2022-05-16
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2022-03-31 was -$13.60M.
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2021-12-31 was -$10.65M.
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2021-09-30 was -$9.63M.
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2021-03-31 was -$18.60M.
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2021 was -$47.60M.
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2020 was -$20.67M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$13.60M 10-Q · filed 2022-05-16 | -$24.25M derived: sum of 2 quarters · filed 2022-05-16 | -$33.88M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2021-12-31 | -$10.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$20.28M derived: sum of 2 quarters · filed 2022-03-07 | -$47.60M 10-K · filed 2022-03-07 | |
| 2021-09-30 | -$9.63M 10-Q · filed 2021-11-08 | -$36.95M 10-Q · filed 2021-11-08 | ||
| 2021-03-31 | -$18.60M 10-Q · filed 2022-05-16 | -$33.46M derived: sum of 2 quarters · filed 2022-05-16 | -$35.72M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$14.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$17.12M derived: sum of 2 quarters · filed 2022-03-07 | -$20.67M 10-K · filed 2022-03-07 | |
| 2020-09-30 | -$2.26M 10-Q · filed 2021-11-08 | -$5.80M 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |